Payden & Rygel’s Biogen BIIB Stock Holding History

Payden & Rygel’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-34	Closed	-$9K	–	112
2016 Q1	$9K	Hold	34	–	–	﹤0.01%	126
2015 Q4	$10K	Buy	+34	New	+$9.77K	﹤0.01%	181

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Payden & Rygel's BIIB Position: Q2 2016 in Review

Payden & Rygel sold out of Biogen (BIIB) in Q2 2016, closing a stake of 34 shares — an estimated $9K sold.

Payden & Rygel first reported a position in BIIB in Q4 2015 and held it in 2 quarters. The position peaked at $10K in Q4 2015. 965 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

Payden & Rygel reported no remaining Biogen position as of Q2 2016 after selling out during the quarter.
Payden & Rygel sold 34 Biogen shares in Q2 2016, an estimated $9K.
Payden & Rygel first reported a position in Biogen in Q4 2015 and held it in 2 quarters.
Payden & Rygel's Biogen position peaked at $10K in Q4 2015.
965 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Payden & Rygel's 13F filing for Q2 2016, filed 5 Aug 2016.